 |
|
|
| |
Resistance Through Week 48 in the DAWNING Study Comparing Dolutegravir (DTG) Plus 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Compared With Lopinavir/Ritonavir (LPV/r) Plus 2 NRTIs in Second-line Treatment
|
| |
| |
Reported by Jules Levin
22nd International AIDS Conference, Amsterdam, Netherlands, July 23-27, 2018
Ruolan Wang,1Joe Horton,2Judy Hopking,3Karen King,2Kimberly Smith,1Michael Aboud,4Brian Wynne,5Jorg Sievers,4Mark Underwood1
1ViiV Healthcare, Research Triangle Park, NC, USA; 2Parexel International, Durham, NC, USA; 3GlaxoSmithKline, Stockley Park, UK; 4ViiV Healthcare, Brentford, UK; 5ViiV Healthcare, Philadelphia, PA, USA
|
| |
|
|
|
|
|
